Welcome back to Research Weekly.
Last week, we covered the FDA briefing documents released ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting. Since then, we’ve spent more time going through the materials.
The headline is important, but the details may be even more useful. The documents offer a clearer look at how the FDA is evaluating these peptides—and why product identity, naming, testing, and documentation matter so much in this market.
As always, the goal here is simple: useful research context, clear takeaways, and less noise.
FDA staff recommends against adding all seven Peptide groups to the 503A Bulks List
The FDA’s current staff recommendations are now clear.
The agency is proposing that the free-base and acetate forms of the following peptide groups not be added to the 503A Bulks List:
BPC-157, KPV, TB-500, MOTS-C, Emideltide (also known as DSIP), Epitalon, Semax
The 503A Bulks List determines which bulk drug substances may be used by certain traditional compounding pharmacies when the substance is not already covered by another permitted category.
This is not a final decision.
The Pharmacy Compounding Advisory Committee will still meet on July 23 and 24 to review the substances, hear presentations, discuss the available evidence, and make recommendations. Those recommendations are advisory and are not legally binding on the FDA.
It is also important to understand what this review does—and does not—mean.
This is not an FDA approval review. It does not establish that these peptides are approved drugs, and it is not a blanket decision about every research-use-only product carrying the same compound name.
The question before the committee is narrower: whether these specific bulk drug substances should be permitted for use in 503A pharmacy compounding.
Why FDA staff is recommending against inclusion
The exact analysis differs from one substance to another, but several concerns appear repeatedly throughout the documents:
limited or absent human clinical evidence
incomplete safety information
uncertain immunogenicity risks
inconsistent naming and chemical characterization
insufficient evidence of historical use in compounding
uncertainty about stability, purity, and manufacturing controls
the availability of FDA-approved alternatives for some of the uses reviewed
The briefing materials also show that several original nominations were withdrawn. Even so, FDA chose to continue evaluating the substances on its own initiative.
That tells us the agency views the issue as significant enough to examine even without an active nomination behind every compound.
The overlooked issue: what exactly does a compound name identify?
One of the most interesting parts of the FDA documents has little to do with marketing claims or popularity.
It is a basic chemistry and quality-control question:
When two products use the same common peptide name, are they actually the same substance?
FDA repeatedly distinguishes between a peptide’s free-base form and its acetate form. Those are considered different bulk drug substances.
The BPC-157 review notes that the original nomination materials were inconsistent about whether the nominated substance was BPC-157 free base or BPC-157 acetate.
The MOTS-C review goes further. FDA notes that multiple salts, derivatives, and potentially different active forms may be sold commercially under the same common name. According to the agency, inconsistent naming can make it difficult to determine exactly which substance a reference standard or finished product represents.
That is not a small technicality.
What happens next?
The advisory committee meeting remains scheduled for July 23–24.
The committee will hear FDA’s analysis, presentations supporting the nominations, public comments, and discussion from independent experts.
The public-comment docket remains open through July 22. Comments received by July 9 are expected to be provided directly to the committee, while later comments submitted before the final deadline may still be considered by FDA.
After the meeting, we’ll be watching for:
the committee’s votes on each substance
whether members agree with FDA staff
discussion of evidence submitted by nominators and the public
how the committee handles free-base and acetate forms
comments on identity, characterization, and testing
any indication of what FDA may do next
We’ll publish a clear summary after the meeting rather than trying to predict the result beforehand.
The next FDA peptide group is already taking shape
The July meeting is not expected to be the end of FDA’s peptide review activity.
FDA has announced another advisory committee meeting to be held before the end of February 2027. A date has not yet been set.
That meeting is expected to consider:
Cathelicidin, also known as LL-37
GHK-Cu
Dihexa acetate
Melanotan II
Pegylated Mechano Growth Factor, or PEG-MGF
Meeting materials and the public-comment docket have not yet been released.
This next group is worth watching because it includes several widely discussed research compounds and raises many of the same questions appearing in the current review: identity, available evidence, safety data, chemical characterization, and manufacturing quality.
We’ll begin covering that review as more information becomes available.
0 comments